(Q88730901)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27830764%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

review article

1 reference

title

Neuroblastoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27830764%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27830764%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

1

Katherine K Matthay

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27830764%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

2

John M Maris

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27830764%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

author name string

Gudrun Schleiermacher

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27830764%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Akira Nakagawara

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27830764%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Crystal L Mackall

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27830764%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Lisa Diller

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27830764%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

publication date

10 November 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27830764%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Disease Primers

27 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27830764%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27830764%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

page(s)

16078

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27830764%20AND%20SRC:MED&resulttype=core&format=json

International variations in the incidence of neuroblastoma.

27 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Accumulation of Segmental Alterations Determines Progression in Neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

The genetic landscape of high-risk neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Activating mutations in ALK provide a therapeutic target in neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Identification of ALK as a major familial neuroblastoma predisposition gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Children's Oncology Group's 2013 blueprint for research: neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Outcome after reduced chemotherapy for intermediate-risk neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Recent advances in neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Neuroblastoma Screening at One Year of Age

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

A population-based study of the usefulness of screening for neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Childhood and adolescent cancer statistics, 2014.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Maternal use of recreational drugs and neuroblastoma in offspring: a report from the Children's Oncology Group (United States)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Maternal hair dye use and risk of neuroblastoma in offspring

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Finding the missing heritability of complex diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Genomic organization and evolution of double minutes/homogeneously staining regions with MYC amplification in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Cancer Stem Cells and Their Interaction with the Tumor Microenvironment in Neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

31 March 2020

Neuroblastoma and MYCN

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Does MYCN Amplification Manifested as Homogeneously Staining Regions at Diagnosis Predict a Worse Outcome in Children with Neuroblastoma? A Children's Oncology Group Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

MINUTE CHROMATIN BODIES IN MALIGNANT TUMOURS OF CHILDHOOD

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Transposition and amplification of oncogene-related sequences in human neuroblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Cell-cycle checkpoints and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Targeted expression of MYCN causes neuroblastoma in transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Telomerase activation by genomic rearrangements in high-risk neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Association of age at diagnosis and genetic mutations in patients with neuroblastoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Focal DNA copy number changes in neuroblastoma target MYCN regulated genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Chromosome 1p and 11q deletions and outcome in neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

1p36 tumor suppression--a matter of dosage?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Correlating telomerase activity levels with human neuroblastoma outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Mechanisms of neuroblastoma regression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Dependence receptor UNC5D mediates nerve growth factor depletion-induced neuroblastoma regression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Update on pediatric opsoclonus myoclonus syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Pediatric reference intervals for plasma free and total metanephrines established with a parametric approach: relevance to the diagnosis of neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Is there a role for PET-CT and SPECT-CT in pediatric oncology?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Ultra-High Density SNParray in Neuroblastoma Molecular Diagnostics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Overall genomic pattern is a predictor of outcome in neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Effectiveness of nationwide screening program for neuroblastoma in Japan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Neuroblastoma Mass Screening in Late Infancy: Insights Into the Biology of Neuroblastic Tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Advances in Risk Classification and Treatment Strategies for Neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Excellent Outcome With Reduced Treatment in Infants With Nonmetastatic and Unresectable Neuroblastoma WithoutMYCNAmplification: Results of the Prospective INES 99.1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Successful treatment of infants with localized neuroblastoma based on their MYCN status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Does aggressive surgical resection improve survival in advanced stage 3 and 4 neuroblastoma? A systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Impact of radiotherapy for high-risk neuroblastoma: a Children’s Cancer Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Local control with multimodality therapy for stage 4 neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Targeting MYCN in neuroblastoma by BET bromodomain inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Neuroblastoma with symptomatic epidural compression in the infant: the AIEOP experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Effect of Increased Immunosuppression on Developmental Outcome of Opsoclonus Myoclonus Syndrome (OMS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

VIP hypersecretion as primary or secondary syndrome in neuroblastoma: A retrospective study by the Société Française des Cancers de l'Enfant (SFCE).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Treatment and outcome of 83 children with intraspinal neuroblastoma: the Pediatric Oncology Group experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Renal carcinoma after childhood cancer: a report from the childhood cancer survivor study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Second malignancies in patients with neuroblastoma: the effects of risk-based therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Growth in children after bone marrow transplantation for advanced neuroblastoma compared with growth after transplantation for leukemia or aplastic anemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Prevalence of advanced bone age in a cohort of patients who received cis-retinoic acid for high-risk neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Diabetes mellitus in long-term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Mutational dynamics between primary and relapse neuroblastomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Emergence of new ALK mutations at relapse of neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Detection of circulating tumor DNA in early- and late-stage human malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Drugging MYCN through an allosteric transition in Aurora kinase A

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

5' flanking sequences of the rat tyrosine hydroxylase gene target accurate tissue-specific, developmental, and transsynaptic expression in transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

GD2 synthase: a new molecular marker for detecting neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

FCGR2APolymorphism Is Correlated With Clinical Outcome After Immunotherapy of Neuroblastoma With Anti-GD2 Antibody and Granulocyte Macrophage Colony-Stimulating Factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

The Neural Crest Migrating into the Twenty-First Century

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Establishing neural crest identity: a gene regulatory recipe

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

The prenatal origins of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

Diagnostic FDG and FDOPA positron emission tomography scans distinguish the genomic type and treatment outcome of neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.78

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRDP.2016.78

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27830764%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

1 reference